Biotalys FIRST LOOK: The regulatory process marches on

Biotalys provided an update on its regulatory review procedure for Evoca in Europe, where the Dutch authority Ctgb has now issued a positive draft assessment report, recommending the approval of Evoca's active ingredient throughout the EU. The draft report follows the earlier decision to allow large-scale demonstration trials with human consumption, and marks an important milestone in the regulatory review. The procedure will now be further followed up by EFSA with Biotalys anticipating full approval in the EU in approx. 12-18 months. We reiterate our € 5.2 TP and Buy rating.